Special Issue

Experimental Methods in Rational Vaccine Design

Message from the Guest Editor

Vaccination is one of the most effective public health measures available. It has been used to treat a number of different communicable diseases, which has even led to the eradication of smallpox for instance. Vaccines have also been used to tackle other disease, in particular in treating cancer, with promising results. During the COVID-19 outbreak, new technologies have been used to develop effective vaccines and the resulting improvements have been used in other fields too. The aim of this special issue is to discuss the improvements and new discoveries that have been made in the field of vaccine design, particularly focusing on new experimental designs. Modern and innovative design is crucial, particular in light of the emerging risk of new pandemics. We are hoping to receive papers that address innovative vaccination strategies, both in their design and in their applications.

Guest Editor

Dr. Laura Franza

Emergency, Anesthesiological and Reanimation Sciences Department, Fondazione Policlinico Universitario A. Gemelli-IRCCS of Rome, Rome, Italy

Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/179810

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

